- Home
- ICCM vs SER Comparison
ICCM vs SER Comparison
Compare ICCM & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | SER |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 19.4M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICCM | SER |
|---|---|---|
| Price | $0.61 | $1.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 150.4K | 98.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | $134.46 |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.47 |
| 52 Week High | $1.53 | $7.92 |
Technical Indicators
Market Signals| Indicator | ICCM | SER |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 36.19 |
| Support Level | $0.59 | $1.53 |
| Resistance Level | $0.62 | $1.86 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 45.76 | 26.92 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.